Epigenetic_regulatory_pathways_in_human_leukaemia-sc-2013-09-24T12:28:21Z-2778
Epigenetic_regulatory_pathways_in_human_leukaemia
3 acute myeloid leukaemic cell lines and 1 control non-small cell lung cancer cell line were treated for 24h with 2 different doses of the KAT2A inhibitor 3-butyrolactone or DMSO vehicle.
Analysis of the role of KAT2A in  maintenance vs. differentiation of human leukaemia.